Enterprise record

Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing muta

Follow
More
Reports & analysis (Directory temporarily unavailable)Alpha EvalSave PDFCompareChallenge a ClaimClaim this record

Alpha ID: alpha:company:8ade0c9b-f391-49c6-a5ab-293476b2586bVersion: public-1As of: unavailable

14 published Claims2 sources

Key Claims

Board and committees

Source-backed public-market identity

Index memberships

Current memberships are attached to a specific security and listing. Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.

No current membership is published in Alpha's tracked index universe.

This is not evidence that the company is absent from every market index.

As of Sep 28, 2026. Rights-filtered public evidence only; no redistribution or model training is granted.

Only source-backed memberships with an explicit public redistribution basis are returned.

Evidence, history and coverage

Additional published Claims

Published evidence records

2 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Alpha canonical company public projection

    canonical identity · Source published: Date unavailable · Retrieved: Sep 28, 2026

    Supports 5 claims
    • Legal Name: Elicio Therapeutics, Inc. · Claim reviewed: Sep 28, 2026
    • Entity Status: Public listing published · Claim reviewed: Sep 28, 2026
    • Published Fact: US · Claim reviewed: Sep 28, 2026
    • Published Fact: Healthcare · Claim reviewed: Sep 28, 2026
    • Published Fact: Biotechnology · Claim reviewed: Sep 28, 2026

  2. Elicio Therapeutics, Inc. DEF 14A 2025-04-09

    sec proxy · Source published: Apr 9, 2025 · Retrieved: Apr 28, 2026

    Supports 9 claims
    • Leadership Role: Allen R. Nissenson, M.D.: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Carol Ashe: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Jay R. Venkatesan, M.D.: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Julian Adams, Ph.D.: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Karen J. Wilson: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Robert Connelly: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Robert R. Ruffolo, Jr., Ph.D.: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Robert R. Ruffolo, Jr., Ph.D., FCPP: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Yekaterina (Katie) Chudnovsky: Director · Claim reviewed: Sep 28, 2026